ROCHE DIABETES CARE LIMITED
Get an alert when ROCHE DIABETES CARE LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£3k
0% vs 2023
Net assets
£10m
+13.3% vs 2023
Employees
34
-51.4% vs 2023
Profit before tax
£1.6m
-8.3% vs 2023
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Accounts not prepared on a going-concern basis
As at 31 December 2024, the Company transferred all of its assets and operations to Roche Diagnostics Ltd, a related entity. Following this transfer, the Company has ceased trading and will not undertake any further commercial activities. As the directors intend to liquidate the company following the settlement of the remaining tax and legal obligations, they have not prepared the financial statements on a going concern basis.
-
4 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
-
Going-concern uncertainty disclosed
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · Δ = latest vs prior filed period · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | Δ vs prior |
|---|---|---|---|---|
| Turnover | £26,197,000 | £21,361,000 | -18.5% | |
| Operating profit | £1,231,000 | £1,272,000 | +3.3% | |
| Profit before tax | £1,753,000 | £1,608,000 | -8.3% | |
| Net profit | £1,267,000 | £1,277,000 | +0.8% | |
| Cash | £3,000 | £3,000 | 0% | |
| Total assets less current liabilities | £9,311,000 | £10,437,000 | +12.1% | |
| Net assets | £9,209,000 | £10,437,000 | +13.3% | |
| Equity | £9,209,000 | £10,437,000 | +13.3% | |
| Average employees | 70 | 34 | -51.4% | |
| Wages | £7,965,000 | £6,457,000 | -18.9% | |
| Directors' remuneration | £485,000 | £289,000 | -40.4% | |
| Directors' pension contributions | £44,000 | £21,000 | -52.3% | |
| Highest paid director | £316,720 | £181,014 | -42.8% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 4.7% | 6.0% | |
| Net margin | 4.8% | 6.0% | |
| Return on capital employed | 13.2% | 12.2% | |
| Gearing (liabilities / total assets) | 37.2% | 0.0% | |
| Current ratio | 2.69x | — | |
| Interest cover | 49.24x | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ROCHE DIABETES CARE LIMITED 2014-07-22 → present
- ROCHE DIABETES CARE (UK) LIMITED 2014-05-23 → 2014-07-22
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Not a going concern (break-up basis)
“As at 31 December 2024, the Company transferred all of its assets and operations to Roche Diagnostics Ltd, a related entity. Following this transfer, the Company has ceased trading and will not undertake any further commercial activities. As the directors intend to liquidate the company following the settlement of the remaining tax and legal obligations, they have not prepared the financial statements on a going concern basis.”
Significant events
- “On 31 December 2024, the directors took the decision to cease trading following the announcement of project Fusion. The Company transferred all of its assets and operations to Roche Diagnostics Ltd, a related entity. Following this transfer, the Company has ceased trading and will not undertake any further commercial activities.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 18 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| PAMBA, Allan | Director | 2026-04-01 | Aug 1971 | British,Kenyan |
| ROWBOTHAM, Kathryn Ryan | Director | 2025-11-02 | Aug 1976 | American |
| UL HAQ, Muhammad Omair | Director | 2025-11-01 | Jul 1989 | Pakistani |
Show 18 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ABIMBOLA, Olufunke | Secretary | 2015-06-22 | 2016-01-01 |
| DANIEL, Richard David | Secretary | 2014-05-23 | 2015-06-22 |
| LISI, Michael | Secretary | 2019-11-19 | 2021-01-20 |
| PAWAN, Catherine Sarah | Secretary | 2021-01-20 | 2026-07-13 |
| REICH, Oren | Secretary | 2016-01-01 | 2019-11-19 |
| APARICIO GONCALVES, Pedro Miguel | Director | 2021-06-29 | 2024-07-01 |
| ERWIN, Richard William | Director | 2024-07-01 | 2025-11-02 |
| GAFFNEY, Sean | Director | 2022-12-05 | 2024-07-01 |
| GMUENDER, Marcel, Dr. | Director | 2020-09-28 | 2021-06-29 |
| GMUENDER, Marcel | Director | 2014-05-23 | 2016-08-25 |
| GOETZL, Michael | Director | 2019-01-01 | 2022-10-25 |
| HARTMANN, Peter Moritz | Director | 2016-08-25 | 2019-07-01 |
| KRUSE, Niklas | Director | 2024-07-01 | 2025-11-01 |
| LEWIS, Brett Stanton | Director | 2014-06-04 | 2018-10-01 |
| MOORE, Bradley Thomas | Director | 2019-07-01 | 2020-09-28 |
| PEARSON, Nicholas Guy | Director | 2014-06-04 | 2024-07-01 |
| SONNENSCHEIN, Edwin, Dr | Director | 2014-05-23 | 2024-07-01 |
| TWIST, Geoffrey John | Director | 2024-07-01 | 2026-04-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Roche Holding (Uk) Limited | Corporate entity | Shares 75–100% | 2016-04-06 | Active |
Filing timeline
Last 20 of 70 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-10-15 | AA | accounts | Accounts with accounts type full | |
| 2026-07-20 | TM02 | officers | Termination secretary company with name termination date | |
| 2026-06-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-04-09 | AP01 | officers | Appoint person director company with name date | |
| 2026-04-09 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-14 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-13 | AP01 | officers | Appoint person director company with name date | |
| 2025-11-13 | TM01 | officers | Termination director company with name termination date | |
| 2025-11-13 | TM01 | officers | Termination director company with name termination date | |
| 2025-09-30 | AA | accounts | Accounts with accounts type full | |
| 2025-06-19 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-10-11 | AA | accounts | Accounts with accounts type full | |
| 2024-07-16 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-15 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-11 | AP01 | officers | Appoint person director company with name date | |
| 2024-07-11 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-11 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-11 | TM01 | officers | Termination director company with name termination date | |
| 2024-07-11 | TM01 | officers | Termination director company with name termination date | |
| 2024-06-17 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 0
- Officers appointed
- 3
- Officers resigned
- 4
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.